nasdaq:prto
|
1070053
|
Oct 30th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
10.00
|
Open
|
Biotechnology
|
Oct 30th, 2020 12:40PM
|
Oct 30th, 2020 12:40PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 29th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
10.00
|
Open
|
Biotechnology
|
Oct 29th, 2020 12:53PM
|
Oct 29th, 2020 12:53PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 28th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
10.00
|
Open
|
Biotechnology
|
Oct 28th, 2020 04:36PM
|
Oct 28th, 2020 04:36PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 27th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 27th, 2020 10:35AM
|
Oct 27th, 2020 10:35AM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 26th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 26th, 2020 03:36PM
|
Oct 26th, 2020 03:36PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 25th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 25th, 2020 12:30PM
|
Oct 25th, 2020 12:30PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 24th, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 24th, 2020 02:40PM
|
Oct 24th, 2020 02:40PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 23rd, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 23rd, 2020 11:59AM
|
Oct 23rd, 2020 11:59AM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 22nd, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 22nd, 2020 09:19AM
|
Oct 22nd, 2020 09:19AM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:prto
|
1070053
|
Oct 21st, 2020 12:00AM
|
Proteon Therapeutics
|
1.1K
|
11.00
|
Open
|
Biotechnology
|
Oct 20th, 2020 10:53PM
|
Oct 20th, 2020 10:53PM
|
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
|
Open
|
|
Open
|
200 West St
|
Waltham
|
MA
|
US
|
02451
|
|
Proteon Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|